Cellectis S.A. (CLLS) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Cellectis S.A. (CLLS) over the past year, gaining 3.0% versus a loss of 80.4%. Over five years, CLLS leads with a -89.4% price change compared with -92.5% for PDSB. PDS Biotechnology is the larger company by market cap ($95.4 million vs $92.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | PDSB |
|---|---|---|
| Share price | $0.9209 | $0.7774 |
| Market cap | $92.76M | $95.39M |
| 1-day change | -7.89% | -3.70% |
| YTD return | -80.97% | +0.96% |
| 1-year return | -80.36% | +2.97% |
| 5-year return | -89.40% | -92.46% |
| EPS (TTM) | $-1.26 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | — |
| Revenue growth (YoY) | +75.76% | — |
| Net income (latest FY) | $-67.59M | $-34.50M |
| Gross margin | 100.00% | — |
| Operating margin | -45.34% | — |
| Net margin | -92.66% | — |
| 52-week high | $5.45 | $1.79 |
| 52-week low | $0.881 | $0.195 |
| Distance from 52-week high | -83.10% | -56.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +497.24% | +478.85% |
| Average volume | 115.00K | 25.64M |
| Shares outstanding | 72.73M | 122.70M |
| Employees | 224 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed CLLS by 83.3 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CLLS vs PDSB FAQ
Which is bigger, Cellectis S.A. or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $92.76M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or PDSB?
PDSB returned +2.97% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.